Ivermectin Accelerates Circulating Nonstructural Protein 1 (NS1) Clearance in Adult Dengue Patients: A Combined Phase 2/3 Randomized Double-blinded Placebo Controlled Trial.

Yupin SuputtamongkolPanisadee AvirutnanDumrong MairiangNasikarn AngkasekwinaiKannika NiwattayakulEakkawit YamasmithFadhil A-Hamad Saleh-ArongAdisak SongjaengTanapan PrommoolNattaya TangthawornchaikulChunya PuttikhuntSaowalak HunnangkulChulaluk KomoltriSuwich ThammapaloPrida Malasit

Published in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021)

A 3-day 1 daily dose of 400 µg/kg oral ivermectin was safe and accelerated NS1 antigenemia clearance in dengue patients. However, clinical efficacy of ivermectin was not observed at this dosage regimen.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
zika virus
prognostic factors
clinical trial
patient reported outcomes
randomized controlled trial
binding protein
amino acid
phase iii
patient reported